Antiretroviral drugs in pediatrics
- 43 Downloads
The advent of potent drugs to treat HIV and the development of increasingly effective treatment strategies have resulted in dramatic improvements in the prognosis and quality of life for HIV-infected children. The purpose of this article is to provide the primary care physicians with practical information on antiretroviral drugs that are currently used for the treatment of pediatric HIV infection.
Key wordsAntiretrovirals HIV Pediatrics
Unable to display preview. Download preview PDF.
- 1.Working Group on Antiretroviral Agents in Pediatric HIV Infection. Guidelines for the use of antiretroviral agents in pediatric HIV infection. January 7, 2000. Website: http://www.hivatis.orgGoogle Scholar
- 11.Fischl M, Greenberg S, Clumeck Net al. Safety and activity of abacavir with 3TC/ZDV in antiretroviralnaïve subjects [abstract 127/12230]. Presented at: The 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland.Google Scholar
- 14.Cadman J. Efavirenz pregnancy warning.Treatment Issues 1998;12:No 3.Google Scholar
- 18.Wiznia A, Stanley K, Krogstad Pet al. Combination nucleoside analogues plus nelfinavir, nevirapine or ritonavir in stable antiretroviral therapy-experienced HIV-infected children [Abstract 697]. Presented at: The 7th Conference on Retroviruses and Opportunistic Infections; January 30–February 2, 2000; San Francisco, USA.Google Scholar
- 19.Hsu A, Granneman G, Chen Set al. Assessment of single- and multiple-dose interactions between ritonavir and saquinavir [abstract LB.B.6041]. Presented at: XIII International AIDS Conference; July 9–14, 2000; Durban, South Africa.Google Scholar
- 24.Church J, Rathore M, Rubio Tet al. A phase III study of amprenavir in protease-inhibitor-naïve and-experienced HIV-infected children and adolescents. Presented at: The 7th Conference on Retroviruses and Opportunistic Infections; January 30–February 2, 2000; San Francisco, USA.Google Scholar
- 26.Hsu A, Isaacson J, Kempf Det al. Trough concentation-EC50 relationship as a predictor of viral response for ABT-378/ritonavir in treatment-experienced patients [abstract 171]. Presented at: The 40th Interscience Conference on Antimicrobial Agent and Chemotherapy; September 17–20, 2000; Toronto, Canada.Google Scholar